Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 29, 2021

Lantern and Deep Lens partner to expedite Phase II NSCLC trial enrolment 

Deep Lens plans to use enrolment criteria defined by Lantern to identify patients and match them to the trial of LP-300.

Lantern Pharma has signed a strategic partnership with Deep Lens to accelerate enrolment in the former’s Phase II clinical trial of LP-300 plus chemotherapy to treat never-smokers with non-small cell lung cancer (NSCLC).

The collaboration will use Deep Lens’ VIPER, an artificial intelligence (AI) clinical trial matching solution, to develop an end-to-end AI-driven drug development pathway to accelerate subject enrolment.

Lantern leverages its RADR AI platform to discover and develop oncology drugs. The company uses machine learning to find biomarker signatures that detect patients who would probably respond to its therapeutic pipeline.

Deep Lens’ VIPER detects, organises and matches cancer patients to trials in real-time for which they may be eligible.

Through the alliance, the companies intend to address two complex and time-taking segments of the drug development process: to match a new molecule with an appropriate indication and detect the right patients for the trials.

Lantern Pharma plans to in-license and advance oncology therapies using genomic data, machine learning and computational biology modelling to detect the patients who would benefit from a therapy and assess the potential underlying mechanisms of action.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Lantern’s small molecule entity, LP-300 is being analysed in multiple randomised, controlled multicentre NSCLC trials.

According to the retrospective analyses of a multinational Phase III trial, LP-300 plus chemotherapy offered substantial improvement in overall survival in the never-smoker subgroup.

LP-300 is set to enter a Phase III trial as a combination treatment for never-smoking NSCLC patients with histologically defined adenocarcinoma.

Using the subject enrolment criteria defined by Lantern, Deep Lens will detect this subgroup of patients and matches them to the LP-300 trial across its network of community oncology centres.

Lantern Pharma president and CEO Panna Sharma said: “Our existing AI platform allows us to predict drug outcomes and response in very specific patient subsets while Deep Lens’ VIPER serves as a tool to find and accelerate the enrollment of appropriate patients for clinical trials.

“We hope to leverage this solution across additional trials and combine it with other advanced AI technologies that align with our mission of accelerating the timeline and reducing the costs of oncology drug discovery and development.”

This June, the Center for Cancer and Blood Disorders (The CenterTX) in the US announced plans to deploy Deep Lens’ AI-based clinical trial screening and enrolment solution VIPER.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU